Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by nikkeron Mar 24, 2016 1:45pm
88 Views
Post# 24698283

RE:RE:"Chance Favours the Prepared Mind"

RE:RE:"Chance Favours the Prepared Mind"

 

GeneNews arranges $5-million private placement

 

2016-03-14 14:46 ET - News Release

 

Mr. James Howard-Tripp reports

GENENEWS LIMITED ANNOUNCES PRIVATE PLACEMENT FINANCING OF UP TO $5 MILLION

GeneNews Ltd. is undertaking a non-brokered private placement of up to 50 million common shares of the company at a price of 10 cents per share. Any remaining unfinanced portion of the offering may be raised with the issuance of a senior secured, collateralized convertible debenture. If needed, this convertible debenture would be issued with a term of one year from date of issue, interest accrued and payable at 15 per cent, and with a conversion price of 16 cents per common share. The conversion would become mandatory if the common shares trade above 16 cents for 30 consecutive trading days. In connection with the offering, GeneNews has applied to the Toronto Stock Exchange for exemption under Section 604(e) of the TSX company manual for a financial hardship exemption, as detailed below.

Bullboard Posts